Name: Tranylcypromine Sulfate
Brand: Selleck Chemicals
SKU: S9464
Availability: InStock
Rating: 5 (9 reviews)

Jump to

Quality Control

Batch: Purity: 99.96%

99.96

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism
Other MAO Inhibitors	Moclobemide (Ro 111163) J147 Sennoside A Paeonol Isatin Norharmane Hypericin Amezinium (methylsulfate) Xanthoangelol Iproniazid

Solubility

In vitro
Batch:

Water : 20 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.1mg/ml (0.27mM)	Taking the 1 mL working solution as an example, add 50 μL of 2 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	364.46	Formula	C₁₈H₂₄N₂O₄S	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	13492-01-8	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

References	[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105177/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2018-10-18)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02717884	UNKNOWN	Acute Myeloid Leukemia; Myelodysplastic Syndrome	Michael Luebbert	2015-05	PHASE1; PHASE2
NCT02273102	COMPLETED	Acute Myelogenous Leukemia; Myelodysplastic Syndromes; Leukemia	University of Miami	2015-03-02	PHASE1
NCT02261779	UNKNOWN	AML	Martin-Luther-Universität Halle-Wittenberg	2014-09	PHASE1; PHASE2
NCT02374567	TERMINATED	Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders	Hannover Medical School	2015-01	PHASE3
NCT00223691	COMPLETED	Autonomic Failure; Orthostatic Hypotension	Vanderbilt University	2002-03	PHASE1
NCT01896349	UNKNOWN	Treatment Resistant Depression	Hospital de Clinicas de Porto Alegre	2013-04

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Tranylcypromine Sulfate MAO inhibitor

Chemical Structure

Molecular Weight: 364.46